Scotia Capital Inc. Vertex Pharmaceuticals Inc Transaction History

Scotia Capital Inc.

  • $17 Billion
  • Q2 2024

A detailed history of Scotia Capital Inc. transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Scotia Capital Inc. holds 7,798 shares of VRTX stock, worth $3.7 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares
7,798
Previous 7,501 3.96%
Holding current value
$3.7 Million
Previous $3.14 Million 16.59%
% of portfolio
0.02%
Previous 0.02%

Shares

28 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024
BUY
$392.81 - $485.53 $116,664 - $144,202
297 Added 3.96%
7,798 $3.66 Million
Q1 2024

May 14, 2024
BUY
$407.69 - $446.08 $90,507 - $99,029
222 Added 3.05%
7,501 $3.14 Million
Q4 2023

Feb 12, 2024
SELL
$343.0 - $410.68 $218,834 - $262,013
-638 Reduced 8.06%
7,279 $2.96 Million
Q3 2023

Nov 14, 2023
SELL
$338.18 - $362.46 $208,657 - $223,637
-617 Reduced 7.23%
7,917 $2.75 Million
Q2 2023

Aug 03, 2023
BUY
$314.42 - $351.91 $116,649 - $130,558
371 Added 4.54%
8,534 $3 Million
Q1 2023

May 11, 2023
SELL
$283.23 - $323.1 $20,109 - $22,940
-71 Reduced 0.86%
8,163 $2.57 Million
Q4 2022

Feb 09, 2023
BUY
$285.76 - $321.48 $38,577 - $43,399
135 Added 1.67%
8,234 $2.38 Million
Q3 2022

Nov 10, 2022
SELL
$273.83 - $305.53 $2.13 Million - $2.38 Million
-7,788 Reduced 49.02%
8,099 $2.35 Million
Q2 2022

Aug 05, 2022
SELL
$234.96 - $292.55 $963,101 - $1.2 Million
-4,099 Reduced 20.51%
15,887 $4.48 Million
Q1 2022

May 09, 2022
SELL
$221.42 - $260.97 $774,305 - $912,612
-3,497 Reduced 14.89%
19,986 $5.22 Million
Q4 2021

Feb 11, 2022
BUY
$177.01 - $223.45 $1.32 Million - $1.67 Million
7,458 Added 46.54%
23,483 $5.16 Million
Q3 2021

Nov 12, 2021
SELL
$181.39 - $202.99 $2.94 Million - $3.29 Million
-16,189 Reduced 50.25%
16,025 $2.91 Million
Q2 2021

Aug 12, 2021
BUY
$187.49 - $221.1 $33,748 - $39,798
180 Added 0.56%
32,214 $6.5 Million
Q1 2021

May 06, 2021
BUY
$207.02 - $241.31 $3.05 Million - $3.56 Million
14,750 Added 85.34%
32,034 $6.88 Million
Q4 2020

Feb 11, 2021
BUY
$207.01 - $276.09 $839,425 - $1.12 Million
4,055 Added 30.65%
17,284 $4.09 Million
Q3 2020

Nov 12, 2020
SELL
$255.65 - $303.1 $547,346 - $648,937
-2,141 Reduced 13.93%
13,229 $3.6 Million
Q2 2020

Aug 11, 2020
SELL
$225.48 - $295.8 $117,475 - $154,111
-521 Reduced 3.28%
15,370 $4.52 Million
Q1 2020

May 15, 2020
SELL
$199.77 - $247.81 $239,923 - $297,619
-1,201 Reduced 7.03%
15,891 $3.78 Million
Q4 2019

Feb 13, 2020
BUY
$166.71 - $223.91 $20,005 - $26,869
120 Added 0.71%
17,092 $3.75 Million
Q3 2019

Nov 14, 2019
SELL
$166.23 - $187.09 $127,830 - $143,872
-769 Reduced 4.33%
16,972 $2.88 Million
Q2 2019

Aug 13, 2019
BUY
$164.61 - $190.37 $97,119 - $112,318
590 Added 3.44%
17,741 $3.26 Million
Q1 2019

May 15, 2019
SELL
$163.73 - $194.7 $12,279 - $14,602
-75 Reduced 0.44%
17,151 $3.15 Million
Q4 2018

Feb 11, 2019
BUY
$151.91 - $192.21 $66,536 - $84,187
438 Added 2.61%
17,226 $2.85 Million
Q3 2018

Nov 14, 2018
SELL
$167.73 - $192.74 $201,779 - $231,866
-1,203 Reduced 6.69%
16,788 $3.24 Million
Q1 2018

May 15, 2018
BUY
$151.6 - $177.13 $87,170 - $101,849
575 Added 3.3%
17,991 $2.93 Million
Q4 2017

Feb 13, 2018
BUY
$137.28 - $155.55 $84,427 - $95,663
615 Added 3.66%
17,416 $2.61 Million
Q3 2017

Nov 14, 2017
SELL
$148.13 - $162.24 $25,033 - $27,418
-169 Reduced 1.0%
16,801 $2.55 Million
Q2 2017

Aug 15, 2017
BUY
N/A
16,970
16,970 $2.19 Million

Others Institutions Holding VRTX

# of Institutions
1,707
Shares Held
226M
Call Options Held
1.2M
Put Options Held
1.59M
View Full List

About VERTEX PHARMACEUTICALS INC

VRTX Quotes by TradingView
  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $122B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Scotia Capital Inc. Portfolio

Follow Scotia Capital Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Scotia Capital Inc., based on Form 13F filings with the SEC.

News

Stay updated on Scotia Capital Inc. with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email